Outlook Therapeutics, Inc. cash flow to debt ratio of -171.65% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Outlook Therapeutics, Inc.'s free cash flow has increased -24.66% from $-68.79M last year to $-51.83M, signaling increasing performance

Outlook Therapeutics, Inc.'s debt to equity ratio is -0.94, signaling that the company spent its equity and risk bankruptcy.

Outlook Therapeutics, Inc.'s debt to equity ratio is -0.94, signaling that the company spent its equity and risk bankruptcy.

Outlook Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Outlook Therapeutics, Inc.'s interest coverage ratio is -193.21, which means that the company struggles to meet interest obligations, signaling financial risk.

Outlook Therapeutics, Inc. has insufficient data to evaluate this check.

Outlook Therapeutics, Inc.'s short-term liabilities of $45.81M exceed its short-term assets of $17.39M, signaling financial risk

Outlook Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Outlook Therapeutics, Inc.'s return on equity of 178.08%, is higher than 15.00%, indicating good performance

Outlook Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Outlook Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Outlook Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Outlook Therapeutics, Inc. has negative free cash flow, indicating cash burn

Outlook Therapeutics, Inc.'s yearly earnings has increased -17.17% since last year from $-75.37M to $-62.42M, signaling increasing performance

Outlook Therapeutics, Inc.'s yearly revenue has increased % since last year from $0.00 to $1.41T, signaling increasing performance

ROIC 5.45K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Outlook Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Outlook Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Outlook Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Outlook Therapeutics, Inc. has insufficient data to evaluate this check.

Outlook Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Outlook Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Outlook Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Outlook Therapeutics, Inc. has insufficient data to evaluate this check.

Outlook Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Outlook Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Outlook Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue